RecruitingInterventionalPhase 1Last updated Aug 11, 2026

Safety and Immunogenicity Study of a Multivalent Gonorrhoea Vaccine

A First in Human Phase I Randomized and Controlled Trial to Test Safety and Immunogenicity of a Multivalent Vaccine Against Neisseria Gonorrhoeae

Overview

ClinicalTrials.gov ID: NCT07758972
Lead Sponsor: LimmaTech Biologics AGINDUSTRY
Brief Summary: The main goal of this trial is to evaluate the safety and immunogenicity of the candidate N. gonorrhoeae vaccine, LTB-NG6.
Study Type: Interventional

Secondary IDs

OTA No. 75A50122C00028Other Grant/Funding Number

HHS/BARDA

224842/Z/21/ZOther Grant/Funding Number

Wellcome Trust

Agreement Dated 1/30/23Other Grant/Funding Number

Germany's Federal Ministry of Research, Technology, and Space (BMFTR)

NNF23SA0088536Other Grant/Funding Number

Novo Nordisk Foundation (NNF)

2026-526168-19-00EU Trial (CTIS) Number

Status

Study Record Dates

NCT05630859Completed

Safety and Efficacy of GSK Neisseria Gonorrhoeae GMMA (NgG) Investigational Vaccine When Administered to Healthy Adults 18 to 50 Years of Age

NCT04870138Completed

Experimental Human Infection With Neisseria Gonorrhoeae (LptA Trial)

NCT04722003Completed

Mucosal Immunity Against Neisseria Gonorrhoeae After 4CMenB Vaccination

NCT04094883Completed

Study to Assess Gonorrhoeae Immune Responses Induced by a N. Meningitidis Vaccine

NCT02459262Completed

Safety and Immunogenicity of a Group B Streptococcus Vaccine in Non-pregnant Women 18-40 Years of Age.

NCT00678652Completed

Phase 1 Safety and Immunogenicity of Meningococcal Vaccine